Karius has raised $165 million in new financing, which it plans to use to further develop its microbial cell-free DNA technology in infectious disease testing.
The Redwood City, CA-based company markets the Karius test, a next-generation sequencing and artificial intelligence-powered option designed to screen blood for 1,000 pathogens, including bacteria, fungi, DNA viruses, and parasites. The test is being positioned for a range of applications, including complicated pneumonia, infections in immunocompromised patients, and endocarditis.
The financing came in a series B round led by SoftBank Vision Fund 2, with participation by General Catalyst, HBM Healthcare Investments, and existing investors.
